Brendon Neuen's Publications

About Brendon Neuen's Publications

Program Lead, Renal and Metabolic
  • Nephrologist and Director, Kidney Trials, Royal North Shore Hospital
  • Clinical Associate Professor, University of Sydney
  • Conjoint Associate Professor, UNSW Sydney
  • Ph.D. ,
  • MBBS(Hons),
  • MSc(Oxon),
  • FRACP,
  • FASN

  • Inflammation as a therapeutic target to improve kidney and cardiovascular outcomes

    Nature Reviews Nephrology Date published:

  • Efficacy and safety of canagliflozin are consistent across polypharmacy burden in CKD: the CREDENCE trial

    Nephrology Dialysis Transplantation Date published:

  • ASN Kidney Health Guidance on the Cardiovascular-Kidney-Metabolic Syndrome

    Journal of the American Society of Nephrology Date published:

  • Finerenone in hypertensive non-diabetic chronic kidney disease: a FIND-CKD subgroup analysis

    European Heart Journal Date published:

  • Hospitalisation Is a Strong Risk Factor for Discontinuation of Sodium-Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes

    Diabetes, Obesity and Metabolism Date published:

  • Cardiovascular Risk Prediction with the Kidney Failure Risk Equation in the Chronic Renal Insufficiency Study

    Kidney360 Date published:

  • Cardiologists as Champions of Kidney Health in the CKM Era

    JACC Date published:

  • Trends in publicly subsidized and private access to GLP-1 medicines indicated for type 2 diabetes in Australia, 2020-2025

    British Journal of Clinical Pharmacology Date published:

  • Non-diabetic kidney disease in patients with diabetes undergoing native kidney biopsy

    Internal Medicine Journal Date published:

  • International Society of Nephrology International Expert Forum: exploring the nexus of cardiovascular-kidney-metabolic health

    Kidney International Date published:

  • A Framework for Risk-Based Implementation of Combination Therapy in CKD

    Clinical Journal of the American Society of Nephrology Date published:

  • Finerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseases

    JAMA Date published:

  • Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease

    JAMA Date published:

  • Finerenone in Persons with Chronic Kidney Disease without Diabetes

    New England Journal of Medicine Date published:

  • Whole-population trends in obesity across dimensions of inequality in England, 2019-25: a retrospective, longitudinal cohort study of 54 million adults

    The Lancet Diabetes & Endocrinology Date published:

  • Efficacy and safety of finerenone in patients with chronic kidney disease: an individual participant data pooled analysis (INFINITY)

    The Lancet Date published: